Breast cancer remains the most prevalent cancer among women globally, according to the WHO (2023). A groundbreaking clinical study led by the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) has introduced a personalized hormonal therapy aimed at optimizing tamoxifen efficacy in patients whose response to the drug has been suboptimal.
Tamoxifen and its Metabolic Challenge
Tamoxifen is a cornerstone in treating hormone receptor-positive breast cancer by blocking estrogen from binding to tumor cell receptors. To be effective, tamoxifen must be metabolized into its active form, (Z)-endoxifen. About one-third of patients have genetically determined limitations in this metabolic conversion due to the enzyme CYP2D6. This deficiency can increase the risk of cancer recurrence by reducing drug effectiveness.
The TAMENDOX Solution
The TAMENDOX study addressed this metabolic issue by supplementing (Z)-endoxifen directly in patients with insufficient tamoxifen conversion. Conducted across 38 clinics in Germany, the multicenter trial involved 235 early-stage hormone-dependent breast cancer patients. Participants were assigned either tamoxifen alone or tamoxifen combined with (Z)-endoxifen for six weeks based on their genetic profiles and blood drug levels.
Results demonstrated that patients receiving the combination therapy achieved therapeutic (Z)-endoxifen levels comparable to those with normal tamoxifen metabolism. This confirms that TAMENDOX effectively overcomes the metabolic barrier, significantly enhancing treatment efficacy.
Clinical Impact and Patient Benefit
Dr. Matthias Schwab, head of IKP, emphasized the significance of this personalized approach:
“With TAMENDOX, we are offering the first effective solution to a long-standing problem: the insufficient effect of tamoxifen in a significant proportion of patients. The results impressively demonstrate how targeted personalized medicine can significantly improve the effectiveness of existing therapies – directly benefiting patients.”
The therapy was well tolerated, with side effects comparable to tamoxifen alone, indicating no additional safety concerns. This approach is especially promising for premenopausal women, who have limited alternatives like aromatase inhibitors.
Conclusion
The IKP is actively pursuing drug approval for TAMENDOX to broaden therapeutic options in breast cancer management. This advancement highlights the importance of personalized medicine in optimizing established treatments and improving patient outcomes.
Related topics
